William Blair analyst Matt Phipps maintained a Hold rating on Kezar Life Sciences (KZR – Research Report) today. The company’s shares closed ...

In a report released today, Andy Hsieh from William Blair maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report). The ...

Stock analysts at William Blair lowered their Q1 2025 EPS estimates for shares of AMN Healthcare Services in a report issued ...

Equities researchers at William Blair decreased their Q3 2025 EPS estimates for shares of CRA International in a research report issued to clients and investors on Friday, February 21st. William Blair ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for General Dynamics (NYSE:GD) from ...

William Blair downgrades Booz Allen, CACI International, Leidos, Parsons and General Dynamics on the heightened risk of ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

We recently compiled a list of the 10 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for General Dynamics (WBAG:GEDY) from Outperform to Market Perform. There are 2,727 funds or institutions reporting ...

Pediatrix Medical reported Q4 revenue of $502.36 million, surpassing estimates, with adjusted EPS of $0.51. The company ...